← Human Trials & Peer-Reviewed Studies
Recombinant growth hormone therapy for cystic fibrosis in children and young adults.
Plain-language guide to PMID 34424546 (2021): systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 34424546
- Journal
- The Cochrane database of systematic reviews
- Year
- 2021
- Study type
- Systematic Review
- Authors
- Thaker V et al. (3 authors)
- DOI
- 10.1002/14651858.CD008901.pub5
- Registered trial
- NCT00803179
What This Paper Covers, in Plain Language
What It Covers
This systematic review looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Cystic fibrosis (CF) is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas.
People with CF often have malnutrition and growth delay.
Who the Included Studies Covered
PubMed indexes the participants as young children, children, teenagers, young adults and adults.
How the Review Was Done
The researchers searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Date of latest search: 12 January 2021.
The researchers also searched ongoing trials registers: clinicaltrials.gov from the United States - date of latest search 19 Jun 2021; WHO International Clinical Trials Registry Platform (ICTRP) - date of latest search 05 March 2018 (not available in 2021).
The researchers conducted a search of relevant endocrine journals and proceedings of the Endocrinology Society meetings using Web of Science, Scopus and Proceedings First.
Date of latest search: 21 Jun 2021.
What Was Measured
Two authors independently screened papers, extracted trial details and assessed their risk of bias.
The researchers assessed the quality of the evidence using the GRADE system.
PubMed files the paper under topics including Cystic Fibrosis, Diabetes Mellitus, Growth Hormone, Human Growth Hormone and Quality of Life.
What This Means in Plain Language
This is a systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 16 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (The Cochrane database of systematic reviews), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.